Regencell Bioscience Holdings Ltd (RGC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Regencell Bioscience Holdings Ltd (RGC) has a cash flow conversion efficiency ratio of -0.243x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.00 Million) by net assets ($8.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Regencell Bioscience Holdings Ltd to measure how much of total assets are equity-financed.
Regencell Bioscience Holdings Ltd - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Regencell Bioscience Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Regencell Bioscience Holdings Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Regencell Bioscience Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regencell Bioscience Holdings Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sinoma International Engineering Co Ltd
SHG:600970
|
0.096x |
|
Bestechnic (Shanghai) Co. Ltd. A
SHG:688608
|
0.042x |
|
Viva Energy Group Ltd
AU:VEA
|
0.227x |
|
Aneka Tambang (Persero) TBK (PT)
AU:ATM
|
-0.079x |
|
CITY DEV.LTD.ADR/1 SD-50
F:CDE0
|
N/A |
|
Metro Brands Limited
NSE:METROBRAND
|
0.076x |
|
IAC Inc.
NASDAQ:IAC
|
0.003x |
|
Stella-Jones Inc.
TO:SJ
|
0.022x |
Annual Cash Flow Conversion Efficiency for Regencell Bioscience Holdings Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Regencell Bioscience Holdings Ltd from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see Regencell Bioscience Holdings Ltd (RGC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $4.86 Million | $-3.11 Million | -0.641x | -31.57% |
| 2024-06-30 | $8.22 Million | $-4.00 Million | -0.487x | -17.62% |
| 2023-06-30 | $11.99 Million | $-4.96 Million | -0.414x | -34.24% |
| 2022-06-30 | $17.08 Million | $-5.27 Million | -0.308x | -260.65% |
| 2021-06-30 | $-4.00 Million | $-767.31K | 0.192x | -29.97% |
| 2020-06-30 | $-2.65 Million | $-726.57K | 0.274x | +28.88% |
| 2019-06-30 | $-1.84 Million | $-390.99K | 0.213x | +144.40% |
| 2018-06-30 | $-855.80 Million | $409.90 Million | -0.479x | +2.12% |
| 2017-06-30 | $-838.90 Million | $410.50 Million | -0.489x | +1.14% |
| 2016-06-30 | $-877.60 Million | $434.40 Million | -0.495x | -26.87% |
| 2015-06-30 | $-894.80 Million | $349.10 Million | -0.390x | +19.77% |
| 2014-06-30 | $-713.40 Million | $346.90 Million | -0.486x | +2.24% |
| 2013-06-30 | $-696.80 Million | $346.60 Million | -0.497x | +19.58% |
| 2012-06-30 | $-570.90 Million | $353.10 Million | -0.618x | -16.90% |
| 2011-06-30 | $-490.30 Million | $259.40 Million | -0.529x | +68.20% |
| 2010-06-30 | $-246.90 Million | $410.80 Million | -1.664x | -49.13% |
| 2009-06-30 | $-242.00 Million | $270.00 Million | -1.116x | +83.40% |
| 2008-06-30 | $-119.00 Million | $800.00 Million | -6.723x | +53.56% |
| 2007-06-30 | $-21.00 Million | $304.00 Million | -14.476x | -216.26% |
| 2006-06-30 | $31.00 Million | $386.00 Million | 12.452x | +128.44% |
| 2005-06-30 | $71.00 Million | $387.00 Million | 5.451x | +813.79% |
| 2004-06-30 | $798.00 Million | $476.00 Million | 0.596x | +103.73% |
| 2003-06-30 | $1.27 Billion | $373.00 Million | 0.293x | -- |
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in… Read more